Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DeathXray33on Sep 18, 2023 10:48am
181 Views
Post# 35641323

RE:RE:RE:RE:RE:Adstiladrin has BlockBuster Potential...

RE:RE:RE:RE:RE:Adstiladrin has BlockBuster Potential...
Benedictus wrote: Yes, while at times I fret over the ongoing liquidity needs and the paltry private placements that come in dribs and drabs, it's worth remembering the bigger picture, which is why we are all here.

An ideal roadmap would be ruvidar being granted BTD by Q1, or sooner. This achievement should hasten partner discussions/negotiations and result in a re-rating of the stock price bringing all outstanding warrants itm. This would also likely bring an end to the begging bowl fundings that have mired the stock price and frustrated investors immensely. 

But the real buyout value of this company is not just with NMIBC's $1.1 - $5B global annual peak sales potential; it is "swinging for the fences" and advancing the pipeline (NSCLC and GBM) to at least ph1 results success, offering a suitor the promise of a foundational and transformative technology, enabling a premium buyout offer for investors. 


I've increased my weekly buying program yet again at any price... Is Rog still buying?
<< Previous
Bullboard Posts
Next >>